Zen-Bio, Inc. Awarded $961,000 Grant From National Institutes of Health (NIH); Proceeds To Fund The Development Of A Human Omental Adipocyte (Fat) Cell System Useful In The Discovery Of The Next Generation Cures And Diagnostic Tools For Obesity Related Diseases
10/19/2005 5:12:28 PM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Sept. 21, 2005--Zen-Bio, Inc, a private closely held biotechnology company, today announced that it was awarded a 24 month $961,578 Phase II SBIR grant from the National Institutes of Health. The phase II application was awarded after the successful completion of Zen-Bio's $100,000 NIH Phase I award. The phase II grant was favorably reviewed by the NIH for both scientific merit and business strategy.
The grant will be used to fund the development and characterization of a human omental adipocyte cell system. "The human omental cell system is a novel research tool invaluable to human metabolic disease researchers," states Dr. Renee Lea-Currie, Zen- Bio's Director of Cell Biology and the grant's Principal Investigator. She went on to state, "Customers will be able to use our human cell system to evaluate potential new drugs and therapies as well as elucidate some of the basic functions of this highly metabolically active endocrine organ."
comments powered by